Figure 3.

MiR-146a-5p sensitizes chemotherapeutic efficacy in vivo. (A) Schematic outline of the combination therapy in a pancreatic xenograft tumor model. (B) MiR-146a-5p expression in transplanted tumors was detected by qPCR (**P < 0.01). (C) Representative images showing the tumors formed in the four treatment groups (n = 5 for each group). (D) Tumor growth curves were drawn according to the measured tumor volumes (**P < 0.01, ***P < 0.001). (E) Tumor weights of the four groups were measured at the 5th week after subcutaneous transplantation (**P < 0.01, ***P < 0.001). (F-G) Representative tumor tissue sections of the xenografts from the four groups were analyzed for the proliferation marker Ki-67 using immunohistochemistry, and the percentages of Ki67-positive cells were measured (scale bar, 40 µm, **P < 0.01).